# SARS-CoV-2 Spike glycoprotein

## COVID-19 XBB.1.5 Novavax 0.5mL/dose (2.5mL/vial)

| TAH Drug Code      | [ICONVXBB](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICONVXBB)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 12 years of age and older.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Patients aged 12 years or older: - Not Previously Vaccinated with Any COVID-19 Vaccine: 0.5 mL IM for 2 doses administered 3 weeks apart. - Previously Vaccinated with Any COVID-19 Vaccine: 0.5 mL IM as a single dose at least 3 months after receipt of a previous dose of COVID-19 vaccine.                                                                                                                                                                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | History of severe allergic reaction to any component of the vaccine or those who experienced a severe allergic reaction after a previous dose of this vaccine.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common: Erythema at injection site (0.7-7.5%), Injection site pain, Swelling at injection site (0.8-8%), Tenderness, Injection site, Nausea, Vomiting, Arthralgia (6.2-23.4%), Myalgia (12.6-50.7%), Headache (15.3-56.9%), Fatigue, Fever (0.4-16.9%), Malaise Serious: Congestive heart failure (0.004%), Heart failure, Myocarditis (0.06%), Pericarditis, Acute cholecystitis (0.02%), Deep venous thrombosis (0.007%), Portal vein thrombosis (0.004%), Thrombosis (0.007%), Thrombosis of mesenteric artery (0.004%), Anaphylaxis, Hypersensitivity reaction (0.1%), Pulmonary embolism (0.02%), Angioedema |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## COVID-19 Vaccine Medigen 0.5mL/dose(10 dose/vial)

| TAH Drug Code      | [ICOVMVC](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOVMVC)                                                                                                                                      |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Medigen COVID-19 Vaccine is indicated for active immunization of individuals 20 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).                                               |
| Dosing             | Age > or = 20 years old: IM: 0.5 mL per dose for 2 doses administered 28 days apart.                                                                                                                            |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                   |
| Contraindications  | History of a severe allergic reaction after a previous dose or to a component of the formulation; history of immediate allergic reaction to a previous dose; known allergy to any component of the formulation. |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea.                                                                    |
| Pregnancy          | Unknown                                                                                                                                                                                                         |
| Lactation          | Unknown                                                                                                                                                                                                         |

## COVID-19 Vaccine Novavax 0.5mL/dose (5mL/vial)

| TAH Drug Code      | [ICOVNVV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOVNVV)                                                                                                                                      |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | COVID-19 Vaccine is indicated for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).                                                       |
| Dosing             | IM, 0.5 mL, > or = 18 years 2 doses administered > or = 3 weeks apart.                                                                                                                                          |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                   |
| Contraindications  | History of a severe allergic reaction after a previous dose or to a component of the formulation; history of immediate allergic reaction to a previous dose; known allergy to any component of the formulation. |
| Adverse Effects    | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea.                                                                    |
| Pregnancy          | Unknown                                                                                                                                                                                                         |
| Lactation          | Unknown                                                                                                                                                                                                         |

